Purpose of this Study
Participants will first receive the study drug and be closely monitored for safety. In the second part, participants will be randomly assigned to receive either the study drug by injection or the standard treatment by IV. Treatment is given in 28 day cycles and may continue for up to 24 cycles.
Who Can Participate?
Eligibility
Participants may be able to join if they are adults with this type of skin cancer. They cannot have received certain similar cancer treatments in the past year, had a lung transplant, or had a lung complication called graft versus host disease. People with cancer that spread to the brain may be eligible if it has not worsened after treatment.
Age Range
18-110
Sex/Genders
Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No
What is Involved?
Description
This study is testing whether a study drug works better than a standard treatment at slowing or stopping advanced skin cancer in people with weakened immune systems. Researchers will also see if either treatment can help shrink the cancer.
Locations
Duke University Hospital
Visit Timing
Weekdays
Compensation
No
Spanish Materials Available
Yes
Study Details
Full Title
Protocol SN2426, A Randomized Phase II Study of Amivantamab (JNJ-61186372) and hyaluronidase (rHuPH20) versus Cetuximab in Immunocompromised Participants with Recurrent Inoperable or Metastatic Cutaneous Squamous Cell Carcinoma
Principal Investigator
Eric
Powers
Protocol Number
PRO00120545
NCT ID
NCT07042295
Phase
II
Enrollment Status
Open to Enrollment